Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699653 | 0.83 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3CXCR4OPRM1 | |
| SCHEMBL3740802 | 0.82 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3CXCR4 | |
| SCHEMBL3747277 | 0.80 | HTR3E (0.33) | SLC6A2SLC6A4SLC6A3CXCR4OPRM1 | |
| SCHEMBL5533233 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CXCR4PDE10A | |
| SCHEMBL3707388 | 0.78 | — | — | |
| SCHEMBL3753480 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL3699707 | 0.77 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3703663 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL3706185 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL3711863 | 0.76 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CXCR4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | SLC6A2 432/4885SLC6A4 1726/4885SLC6A3 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.